Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Tables)

v3.20.2
Subsequent Events (Tables)
9 Months Ended
Sep. 30, 2020
Subsequent Events [Abstract]  
Schedule of Pro Forma Table Shows the Number of Issued and Outstanding Shares

The following pro forma table shows the number of issued and outstanding shares of our common stock as a result of the underwritten offering, which closed on October 6, 2020 as if the shares were all issued and outstanding as of September 30, 2020:

 

    September 30, 2020  
Actual shares issued and outstanding     5,765,566  
Shares sold in the underwritten common stock offering which closed on October 6, 2020     4,800,000  
Conversion of the $700,000 LOC with DKBK and related accrued interest on October 6, 2020     199,537  
Shares to be issued as a result of triggering the anti-dilution provision of previously issued shares of common stock     1,156,480  
Shares to be issued to Yuhan Corporation, Elion Oncology, Inc. and Aposense Ltd. in connection with the respective license agreements.     1,700,000  
Restricted stock awards that vested on the completion of our underwritten offering and up-list to the Nasdaq Capital Market on October 6, 2020     214,078  
Pro forma shares issued and outstanding     13,835,661